TD Cowen Maintains Buy on Grace Therapeutics, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 64.4%

Neg 64.4% Neu 0% Pos 0%

TD Cowen analyst Stacy Ku maintains Grace Therapeutics (NASDAQ:GRCE) with a Buy and lowers the price target from $12 to $8.